Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Graham G Russell

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Bone|May 22, 2020
History of alendronateSteven R Cummings, Arthur C Santora, Dennis M Black, et al.
Therapeutics and Clinical Risk Management|April 12, 2011
Atrial fibrillation and the use of oral bisphosphonatesMichael Pazianas, Cyrus Cooper, Yiting Wang, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 7, 2012
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort StudyM Pazianas, B Abrahamsen, P A Eiken, et al.
The Journal of Biological Chemistry|May 16, 2006
The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product bindingKathryn L Kavanagh, James E Dunford, Gabor Bunkoczi, et al.
British Journal of Clinical Pharmacology|January 17, 2019
Pharmacology of bisphosphonatesSerge Cremers, Matthew T Drake, F Hal Ebetino, et al.
Journal of Biomedical Materials Research. Part A|October 2, 2007
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitroZachary J Henneman, George H Nancollas, F Hal Ebetino, et al.
Molecular Cancer Therapeutics|December 11, 2007
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosisRachel M Locklin, Ermanno Federici, Belen Espina, et al.
International Journal of Cancer|April 19, 2006
Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cellsAnke J Roelofs, Philippa A Hulley, Annemieke Meijer, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 7, 2007
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductaseAnke J Roelofs, Claire M Edwards, R Graham G Russell, et al.
Stem Cells (Dayton, Ohio)|December 19, 2015
Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their FunctionJuhi Misra, Sindhu T Mohanty, Sanjeev Madan, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Bone|May 22, 2020
History of alendronateSteven R Cummings, Arthur C Santora, Dennis M Black, et al.
Therapeutics and Clinical Risk Management|April 12, 2011
Atrial fibrillation and the use of oral bisphosphonatesMichael Pazianas, Cyrus Cooper, Yiting Wang, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 7, 2012
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort StudyM Pazianas, B Abrahamsen, P A Eiken, et al.
The Journal of Biological Chemistry|May 16, 2006
The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product bindingKathryn L Kavanagh, James E Dunford, Gabor Bunkoczi, et al.
British Journal of Clinical Pharmacology|January 17, 2019
Pharmacology of bisphosphonatesSerge Cremers, Matthew T Drake, F Hal Ebetino, et al.
Journal of Biomedical Materials Research. Part A|October 2, 2007
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitroZachary J Henneman, George H Nancollas, F Hal Ebetino, et al.
Molecular Cancer Therapeutics|December 11, 2007
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosisRachel M Locklin, Ermanno Federici, Belen Espina, et al.
International Journal of Cancer|April 19, 2006
Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cellsAnke J Roelofs, Philippa A Hulley, Annemieke Meijer, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 7, 2007
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductaseAnke J Roelofs, Claire M Edwards, R Graham G Russell, et al.
Stem Cells (Dayton, Ohio)|December 19, 2015
Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their FunctionJuhi Misra, Sindhu T Mohanty, Sanjeev Madan, et al.
Pageof 7